Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Angiogenesis >> Integrin

Integrin

Intergrin is a cell adhesion receptor for extracellular matrix protein binding. It is also involved in cell to cell interaction and triggers a variety of signaling pathways for cell proliferation, survival and mobility etc.

Products for  Integrin

  1. Cat.No. Product Name Information
  2. GC37975 α2β1 Integrin Ligand Peptide α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. α2β1 Integrin Ligand Peptide Chemical Structure
  3. GC38873 α2β1 Integrin Ligand Peptide TFA α2β1 Integrin Ligand Peptide TFA Chemical Structure
  4. GC68390 α5β1 integrin agonist-1 α5β1 integrin agonist-1 Chemical Structure
  5. GC62380 αvβ1 integrin-IN-1 αvβ1 integrin-IN-1 (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. αvβ1 integrin-IN-1 Chemical Structure
  6. GC62566 αvβ1 integrin-IN-1 TFA αvβ1 integrin-IN-1 TFA Chemical Structure
  7. GC64932 αvβ5 integrin-IN-1 αvβ5 integrin-IN-1 is a first potent and selective αvβ5 integrin inhibitor (pIC50 = 8.2) . αvβ5 integrin-IN-1 Chemical Structure
  8. GC69837 (R/S)-Alicaforsen

    (R/S)-ISIS-2302

    (R/S)-Alicaforsen is the racemic form of Alicaforsen, which consists of both R and S configurations. Alicaforsen is a 20-base length antisense oligonucleotide that inhibits the production of ICAM-1, an important adhesion molecule involved in the migration and transport process of white blood cells to inflammatory sites.

     (R/S)-Alicaforsen Chemical Structure
  9. GC74710 2-Methylbutyrylcarnitine chloride 2-Metlbutyrylcarnitine (chloride) is a gut microbial metabolite which binds to integrin α2β1 in platelets, potentiating cytosolic phospholipase A2 (cPLA2) activation and platelet perresponsiveness. 2-Methylbutyrylcarnitine chloride Chemical Structure
  10. GC15557 A 205804 A 205804 is a potent and selective lead inhibitor of E-selectin and ICAM-1 expression (E-selectin: IC50 = 20nM; ICAM-1: IC50 = 25nM). A 205804 Chemical Structure
  11. GC15192 A 286982 A LFA-1/ICAM-1 interaction inhibitor A 286982 Chemical Structure
  12. GC74346 A20FMDV2 A20FMDV2 is a selective αvβ6 integrin inhibitor (IC50: 3 nM), with an activity 1,000-fold more selective for αvβ6 than for other RGD-directed integrins (αvβ3, αvβ5, and α5β1). A20FMDV2 Chemical Structure
  13. GC65597 Abciximab

    C7E3

    Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor.

     Abciximab Chemical Structure
  14. GC68594 Abituzumab

    EMD 525797; DI17E6

    Abituzumab (DI17E6) is a humanized monoclonal antibody (IgG2 type) against integrin αV. Abituzumab can effectively reduce the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, especially for prostate cancer.

     Abituzumab Chemical Structure
  15. GC34133 ATN-161 ATN-161 is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model. ATN-161 Chemical Structure
  16. GC33837 ATN-161 trifluoroacetate salt (ATN-161 TFA salt)

    Ac-PHSCN-NH2, PHSCN Peptide

     ATN-161 trifluoroacetate salt (ATN-161 TFA salt) is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model. ATN-161 trifluoroacetate salt (ATN-161 TFA salt) Chemical Structure
  17. GC68754 Bersanlimab

    BI-505

    Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anti-cancer effects.

     Bersanlimab Chemical Structure
  18. GC65909 Bexotegrast

    PLN-74809

     Bexotegrast is a potent inhibitor of αΝβ6 integrin. Bexotegrast can be used for researching fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP) (extracted from patent WO2020210404A1, compound 5). Bexotegrast Chemical Structure
  19. GC17560 BIO 1211 An α4β1 inhibitor,selective and high affinity BIO 1211 Chemical Structure
  20. GC14208 BIO 5192 α4β1 inhibitor BIO 5192 Chemical Structure
  21. GC60077 BIO5192 hydrate BIO5192 hydrate is a selective and potent integrin α4β1 (VLA-4) inhibitor (Kd<10 pM). BIO5192 hydrate Chemical Structure
  22. GC50078 BIRT 377 Potent negative allosteric modulator of LFA-1 BIRT 377 Chemical Structure
  23. GC62872 BMS-587101 BMS-587101 is a potent and orally active antagonist of leukocyte function associated antigen-1 (LFA-1). BMS-587101 Chemical Structure
  24. GC38893 BMS-688521 BMS-688521 is a highly potent, orally active inhibitor of the LFA-1/ICAM interaction, with an IC50 of 2.5 nM in the adhesion assay and an IC50 of 60 nM in the MLR assay. BMS-688521 Chemical Structure
  25. GC50325 BOP BOP is a potent and selective dual α9β1/α4β1 integrin inhibitor with Kd values in the picomolar range. BOP Chemical Structure
  26. GC73519 BT200 sodium BT200 sodium, a pegylated form of the aptamer BT100, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis. BT200 sodium Chemical Structure
  27. GC50075 BTT 3033 Selective inhibitor of integrin α2β1 BTT 3033 Chemical Structure
  28. GC38128 c(phg-isoD-G-R-(NMe)k) TFA c(phg-isoD-G-R-(NMe)k) TFA Chemical Structure
  29. GC65455 c(phg-isoDGR-(NMe)k) c(phg-isoDGR-(NMe)k) is a selective and potent α5β1-integrin ligand with an IC50 of 2.9 nM. c(phg-isoDGR-(NMe)k) Chemical Structure
  30. GC32042 Carotegrast

    HCA2969

     Carotegrast is an orally available α4 integrin receptor inhibitor with anti-inflammatories activities. Carotegrast Chemical Structure
  31. GC62143 Carotegrast methyl

    AJM300

     Carotegrast methyl (AJM300) is an orally active and selective α4 integrin antagonist. Carotegrast methyl Chemical Structure
  32. GC68856 Certepetide

    CEND-1; iRGD

    Certepetide (CEND-1) is a dual-function cyclic peptide (also known as iRGD). Certepetide is a penetrable tumor peptide that interacts with alpha-v integrins through its RGD motif and activates neuropilin-1 (NRP-1), thereby transforming the solid tumor microenvironment into temporary active molecular channels. Certepetide can accumulate in tumors and can be used for research on pancreatic cancer and other solid tumors.

     Certepetide Chemical Structure
  33. GC13559 Cilengitide

    EMD 121974

     Integrin inhibitor for αvβ3 and αvβ5 Cilengitide Chemical Structure
  34. GC61520 Cilengitide TFA

    EMD 121974 TFA

     Cilengitide is a potent and selective integrin inhibitor for αvβ3 and αvβ5 receptor, with IC50 values of 4 nM and 79 nM, respectively. Cilengitide TFA Chemical Structure
  35. GC74401 cRGDfK-thioacetyl ester TFA cRGDfK-thioacetyl ester TFA is a bioactive polypeptide molecule. cRGDfK peptide has a selective affinity for integrins. cRGDfK peptide can modify NIR fluorescent probes for cancer targeting imaging. cRGDfK-thioacetyl ester TFA Chemical Structure
  36. GN10535 Cucurbitacin B

    Cuc B, NSC 49451, NSC 144154

     Cucurbitacin B Chemical Structure
  37. GC13050 CWHM-12 An inhibitor of αV integrins CWHM-12 Chemical Structure
  38. GC17610 Cyclo (-RGDfK)

    Cyclo(-Arg-Gly-Asp-D-Phe-Lys)

     An inhibitor of αvβ3 integrin Cyclo (-RGDfK) Chemical Structure
  39. GC60117 Cyclo(-RGDfK) TFA Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface. Cyclo(-RGDfK) TFA Chemical Structure
  40. GC68921 Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA

    Cyclo(RGDfC) TFA

    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA is a cyclic RGD peptide with high affinity for αvβ3 integrin, which can disrupt cell adhesion. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA inhibits the expression of pluripotency genes in embryonic stem cells (ESC), and suppresses the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used for tumor-related research.

     Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA Chemical Structure
  41. GC34141 Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) is an inhibitor of integrin αvβ3, with antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA Chemical Structure
  42. GC30111 Cyclo(RADfK) Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis. Cyclo(RADfK) Chemical Structure
  43. GC13923 Cyclo(RGDyK) trifluoroacetate Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with IC50 of 20 nM. Cyclo(RGDyK) trifluoroacetate Chemical Structure
  44. GC19128 E7820

    ER68203-00

     E7820 is an angiogenesis inhibitor by suppressing integrin a2, a cell adhesion molecule expressed on endothelial cells. E7820 Chemical Structure
  45. GC62182 Echistatin TFA Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin TFA Chemical Structure
  46. GC17236 Echistatin, α1 isoform Echistatin, α1 isoform, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin, α1 isoform Chemical Structure
  47. GC69041 Efalizumab

    Efalizumab is a targeted T-cell modulator, which is a humanized monoclonal antibody against the LFA-1 alpha subunit CD11a. Efalizumab can inhibit T-cell activation, skin T-cell trafficking and T-cell adhesion to keratinocytes, and can be used in research on plaque psoriasis.

     Efalizumab Chemical Structure
  48. GC70986 Egaptivon pegol sodium Egaptivon pegol sodium is an aptamer, which blocks binding of the von Willebrand Factor (VWF) to platelet GPIb receptors. Egaptivon pegol sodium Chemical Structure
  49. GC69057 EMD527040

    EMD527040 is a highly efficient and selective αvβ6 antagonist with anti-fibrotic activity. It can be used for research on liver cancer and liver fibrosis.

     EMD527040 Chemical Structure
  50. GC69067 Enlimomab

    BI-RR 0001; Anti-Human IL6 Recombinant Antibody

    Enlimomab (BI-RR 0001) is a mouse IgG2a monoclonal antibody targeting human ICAM-1, which can inhibit leukocyte adhesion to vascular endothelium, thereby reducing leukocyte extravasation and inflammatory tissue damage. Enlimomab has anti-inflammatory effects and can be used in stroke research.

     Enlimomab Chemical Structure
  51. GC12447 Eptifibatide Acetate

    Glycoprotein (GP) IIb/IIIa inhibitor

     Eptifibatide Acetate Chemical Structure
  52. GC68283 Etrolizumab

    rhuMAb Beta7; RG7413; PRO145223

     Etrolizumab Chemical Structure
  53. GC14804 Firategrast Firategrast Chemical Structure
  54. GC32562 Fradafiban (BIBU-52) Fradafiban (BIBU-52) is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM. Fradafiban (BIBU-52) Chemical Structure
  55. GC70223 Fradafiban hydrochloride Fradafiban (BIBU-52) hydrochloride is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM. Fradafiban hydrochloride Chemical Structure
  56. GC19167 GLPG0187 An αν?integrin receptor antagonist GLPG0187 Chemical Structure
  57. GC30223 Gly-Arg-Gly-Asp-Ser Gly-Arg-Gly-Asp-Ser is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser Chemical Structure
  58. GC13951 GR 144053 trihydrochloride platelet fibrinogen receptor glycoprotein IIb/IIIa (GpIIb/IIIa) antagonist GR 144053 trihydrochloride Chemical Structure
  59. GC33323 GRGDSP GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor. GRGDSP Chemical Structure
  60. GC34265 GRGDSP TFA GRGDSP (TFA) is an integrin inhibitor. GRGDSP TFA Chemical Structure
  61. GC11753 HSDVHK-NH2

    P11

    HSDVHK-NH2 is an inhibitor of the interaction between integrin αvβ3 and vitronectin, with an IC50 value of 1.74 pg/mL (2.414 pM).

     HSDVHK-NH2 Chemical Structure
  62. GC34301 ILK-IN-2

    CPD 22, Integrin-linked Kinase Inhibitor 1, OSU-T 315

     ILK-IN-2 (OSU-T315 analog) is a ILK inhibitor. ILK-IN-2 Chemical Structure
  63. GC60200 ILK-IN-3 ILK-IN-3 is an integrin linked kinase inhibitor with antitumor activity. ILK-IN-3 Chemical Structure
  64. GC32967 Integrin Antagonists 27 Integrin Antagonists 27 is a small molecule integrin αvβ3 antagonist with binding affinity of 18 nM, as s novel anticancer agent. Integrin Antagonists 27 Chemical Structure
  65. GC61613 Integrin modulator 1 Integrin modulator 1 is a potent and selective α4β1 integrin agonist, with an IC50 of 9.8 nM for RGD-binding α4β1. Integrin modulator 1 Chemical Structure
  66. GC32787 iRGD peptide (c(CRGDKGPDC))

    c(CRGDKGPDC)

     iRGD peptide (c(CRGDKGPDC)) is a cyclic peptide composed of 9 amino acids that can specifically bind to av integrin and then be enzymatically hydrolyzed to produce CRGDK/R, which interacts with neuropilin-1 (NRP-1), thereby triggering drug tissue penetration and having tumor targeting and tumor penetration properties. iRGD peptide (c(CRGDKGPDC)) Chemical Structure
  67. GC38801 Irigenin Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells. Irigenin Chemical Structure
  68. GC50642 LDV α4β1 (VLA-4) ligand LDV Chemical Structure
  69. GC16190 LDV FITC fluorescent ligand that binds to the α4β1 integrin (VLA-4) LDV FITC Chemical Structure
  70. GC17263 Leukadherin 1 CD11b/CD18 activator Leukadherin 1 Chemical Structure
  71. GC19222 Lifitegrast

    SAR 1118

     Lifitegrast is an integrin lymphocyte function-associated antigen-1 (LFA-1) antagonist; inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast Chemical Structure
  72. GC36500 LXW7 LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 Chemical Structure
  73. GC32055 MK-0429 (L-000845704)

    L-000845704

     MK-0429 (L-000845704) (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1, respectively. MK-0429 (L-000845704) Chemical Structure
  74. GC10048 MNS

    3,4Methylenedioxyβnitrostyrene, NSC 10120, NSC 105303, NSC 170724, Syk Inhibitor III

     Inhibitor of Src/Syk tyrosine kinases MNS Chemical Structure
  75. GC61109 Natalizumab Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab Chemical Structure
  76. GC16107 Obtustatin An integrin α1β1 inhibitor Obtustatin Chemical Structure
  77. GC74342 Obtustatin triacetate Obtustatin triacetate is a 41-residue non-RGD disintegrin. Obtustatin triacetate Chemical Structure
  78. GC69630 Orbofiban acetate

    Orbofiban acetate is an orally active platelet membrane glycoprotein IIb/IIIa antagonist that inhibits platelet aggregation.

     Orbofiban acetate Chemical Structure
  79. GC36821 OSU-T315 OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain). OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner. OSU-T315 causes cell death through apoptosis and autophagy. OSU-T315 Chemical Structure
  80. GC67708 PLN-1474 PLN-1474 Chemical Structure
  81. GC10184 RGD (Arg-Gly-Asp) Peptides RGD (Arg-Gly-Asp) Peptides is a tripeptide that can bind to integrins, effectively induce cell adhesion, locate a specific cell line and produce a specific cellular response. RGD (Arg-Gly-Asp) Peptides Chemical Structure
  82. GC37524 RGD peptide (GRGDNP) TFA RGD peptide (GRGDNP) TFA Chemical Structure
  83. GC34402 RGD Trifluoroacetate RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; RGD Trifluoroacetate binds to integrins. RGD Trifluoroacetate Chemical Structure
  84. GC16385 RGDS peptide

    Fibronectin Inhibitor, HArgGlyAspSerOH

     RGDS peptide is an integrin binding sequence that inhibits integrin receptor function. RGDS peptide Chemical Structure
  85. GC37541 Risuteganib Risuteganib Chemical Structure
  86. GC62397 RO0270608 RO0270608, the active metabolite of R411, is a dual alpha4beta1-alpha4beta7 (α4β1/α4β7) integrin antagonist. RO0270608 Chemical Structure
  87. GC72461 Rovelizumab Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab Chemical Structure
  88. GC14795 RWJ 50271 LFA-1/sICAM interaction inhibitor RWJ 50271 Chemical Structure
  89. GC14143 SB273005

    An αvβ3 antagonist

     SB273005 Chemical Structure
  90. GC64571 Sibrafiban

    RO 48-3657

     Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-prodrug of Ro 44-3888 and a selective glycoprotein IIb/IIIa receptor antagonist. Sibrafiban Chemical Structure
  91. GC31993 SR121566A SR121566A is a novel non-peptide Glycoprotein IIb/IIIa (GP IIb-IIIa) antagonist, which can inhibit ADP-, arachidonic acid- and collagen-induced human platelet aggregation with IC50s of 46±7.5, 56±6 and 42±3 nM, respectively. SR121566A Chemical Structure
  92. GC74395 Synstatin (92-119)

    SSTN92-119

     Synstatin (92-119) is an anti-tumor agent that inhibits angiogenesis and cancer cell invasion. Synstatin (92-119) Chemical Structure
  93. GC12037 TC-I 15 α2β1 integrin inhibitor TC-I 15 Chemical Structure
  94. GC18025 TCS 2314 integrin very late antigen-4 (VLA-4; α4β1) antagonist TCS 2314 Chemical Structure
  95. GC61323 Tetrac Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities. Tetrac Chemical Structure
  96. GC13255 Tirofiban selective platelet GPIIb/IIIa antagonist Tirofiban Chemical Structure
  97. GC11371 Tirofiban hydrochloride monohydrate A GPIIb/IIIa antagonist Tirofiban hydrochloride monohydrate Chemical Structure
  98. GC37818 TR-14035 TR-14035 is a orally active dual α4β7/α4β1 integrin antagonist, with IC50 s of 7 nM and 87 nM for α4β7 and α4β1, respectively. TR-14035 Chemical Structure
  99. GC63490 Valategrast

    R-411 free base

     Valategrast (R-411 free base) is a potent and orally active integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast Chemical Structure
  100. GC64212 Valategrast hydrochloride

    R-411

     Valategrast hydrochloride (R-411) is a potent integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast hydrochloride Chemical Structure
  101. GC34211 Vedolizumab Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease. Vedolizumab Chemical Structure

Items 1 to 100 of 105 total

per page
  1. 1
  2. 2

Set Descending Direction